FDA Issues Guidance on Drugs Containing Nanomaterials

News
Article

The draft guidance provides guidance on the development of drugs and biologics in which a nanomaterial is present in the finished dosage form.

On Dec. 15, 2017, FDA published draft guidance outlining the agency’s thoughts on the development of drugs and biologics that contain nanomaterials in the finished dosage form. Nanomaterials used in drug products may include inactive and active ingredients that may result in product attributes that differ from products that do not contain nanomaterials. Therefore, the agency feels these materials need particular examination.

The new guidance is one of several the agency has published related to nanotechnology. This guidance is targeted to applicants and sponsors of investigational, premarket, and postmarket submissions of products containing nanomaterials. It addresses “general principles and specific considerations for the development of drug products containing nanomaterials, including considerations for establishing the equivalence of such products with other drugs.”

The guidance provides a risk-based framework and discusses risk factors for these types of products. Chemistry, manufacturing, and controls regarding these products is also discussed, as well as environmental impacts.

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.